NAMS CSO Sold $3.4M Before Phase 3 Data Readout
NewAmsterdam Pharma's Chief Scientific Officer sold $3.4M worth of shares on August 24, immediately before the company's Phase 3 Obicetrapib data readout at ESC 2026 congress. The timing creates tensi
NAMS CSO Sold $3.4M Before Phase 3 Data Readout
NEW YORK, September 9 —
NewAmsterdam Pharma Company N.V. (NAMS) Chief Scientific Officer Johannes Kastelein sold 125,000 shares at $26.91 on August 24 for $3.36 million, immediately before the company's Phase 3 Obicetrapib data readout at the ESC 2026 congress. The stock now trades at $25.63, below his exit price, while the analyst consensus target stands at $51.58. Both cannot be right.
- Kastelein sold $3.36 million in shares at $26.91 on August 24; stock has since fallen to $25.63.
- Analyst consensus price target $51.58 implies 101% upside from the current price.
- $630 million cash, zero debt; operating cash flow -$143 million over the trailing twelve months.
The Sell Before the Readout
Kastelein, whose role most directly requires assessing Obicetrapib's clinical prospects, exercised 125,000 options and sold all resulting shares on the same day, August 24, per SEC Form 4 filings, collecting $3.36 million at $26.91. The timing frames the question: the sale came ahead of the Phase 3 data presentation at the European Society of Cardiology 2026 congress. Insider ownership stands at just 0.9% of shares outstanding, a figure thin even before this transaction. Short sellers hold 12.4% of the float, suggesting skepticism about the ESC catalyst was not confined to insiders.
The Pipeline the Analysts Are Buying
NewAmsterdam Pharma Company N.V. is a late-stage cardiovascular biotech with roughly 100 employees and one lead asset: Obicetrapib, an oral CETP inhibitor in Phase 3 trials for LDL-C lowering, with a Phase 2a Alzheimer's extension as a second potential indication. The balance sheet is the company's clearest strength: $630 million in cash, zero debt, providing runway at a $143 million annual operating cash burn. Analysts set a $51.58 consensus target, implying 101% upside; that bet sits alongside three EPS misses in the last four quarters, including two exceeding 46%. The DCF calculator can stress-test what Phase 3 success would need to deliver to justify a doubling.
| Ticker | Mkt cap | Fwd P/E | 52-wk |
|---|---|---|---|
| NAMS | $3.0B | n/a | -5.6% |
| MLYS | $2.8B | n/a | -26.7% |
| EWTX | $4.8B | n/a | +193.6% |
| IRON | $3.0B | n/a | +32.2% |
| ELVN | $4.4B | n/a | +200.8% |
| APGE | $10.2B | n/a | +260.3% |
What ESC Resolves and What It Does Not
The ESC 2026 congress is the fulcrum. If Phase 3 Obicetrapib data shows clinically significant LDL-C reduction with a clean safety profile, the analyst $51.58 consensus target has its foundation and the CSO's August exit becomes portfolio housekeeping. If the data disappoints or raises safety signals, the insider sell-down before the readout looks prescient. Institutional ownership of 105.7% of shares outstanding, inflated by short mechanics, and free cash flow of -$45 million over the trailing twelve months frame the stakes. Run the free NewAmsterdam Pharma Company N.V. deep-dive to track the fundamentals heading into the ESC window.
Basis Report is independent research for informational purposes. It is not investment advice and not a recommendation to buy or sell any security.
Frequently Asked Questions
When did NAMS CSO sell $3.4M in shares?
Johannes Kastelein, NAMS's Chief Scientific Officer, sold 125,000 shares at $26.91 per share on August 24 for $3.36 million. The sale occurred immediately before the company's Phase 3 Obicetrapib data readout at ESC 2026 congress.
What is NAMS's drug Obicetrapib used for?
Obicetrapib is an oral CETP inhibitor currently in Phase 3 trials for LDL-C lowering. NAMS is also exploring Phase 2a in Alzheimer's disease as a potential second indication.
What is the NAMS analyst price target?
The analyst consensus price target for NAMS is $51.58, implying 101% upside from the current price of $25.63. This bullish stance contrasts with three EPS misses in the last four quarters.
What will Phase 3 results mean for NAMS?
If Phase 3 Obicetrapib shows clinically meaningful LDL-C reduction with a clean safety profile, the analyst bull case strengthens. If results disappoint or raise safety concerns, the CSO's August exit becomes the story.
How much cash does NAMS have?
NAMS has $630 million in cash with zero debt, providing runway at $143 million annual operating cash burn. This strong balance sheet allows development funding through key catalysts like the ESC readout.
NewAmsterdam Pharma's Chief Scientific Officer sold $3.36 million in shares on August 24 at $26.91 — and the stock has since fallen to $25.63, below his exit price — even as the company prepares to present Phase 3 Obicetrapib data at the ESC 2026 congress. The question investors must now answer: is the upcoming data readout the catalyst analysts are pricing in, or one the company's own top scientist has already priced out?